Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliografía
[1]
Rajkumar SV. Clinical course and management of monoclonal gammopathy of undetermined significance. En: Kyle RA, Connor RF, eds. UpToDate; 2018. Disponible en: https://www.uptodate.com/contents/clinical-course-and-management-of-monoclonal-gammopathy-of-undetermined-significance (consultado 23 de mayo de 2019).
[2]
Rajkumar SV. Diagnosis of monoclonal gammopathy of undetermined significance. En: Kyle RA, Connor RF, eds. UpToDate; 2018. Disponible en: https://www.uptodate.com/contents/diagnosis-of-monoclonal-gammopathy-of-undetermined-significance?topicRef=15772&source=see_link (consultado 23 de mayo de 2019).
[3]
Galego García A, Amor Otero MA. Gammapatías monoclonales. Guías clínicas Fisterra. Disponible en: https://www.fisterra.com/guias-clinicas/gammapatias-monoclonales/ (consultado 23 de mayo de 2019).
[4]
R.A. Kyle, T.M. Therneau, S.V. Rajkumar, D.R. Larson, M.F. Plevak, J.R. Offord, et al.
Prevalence of monoclonal gammopathy of undetermined significance.
N Engl J Med, (2006), 354 pp. 1362-1369
[5]
T.M. Therneau, R.A. Kyle, L.J. Melton 3rd, D.R. Larson, J.T. Benson, C.L. Colby, et al.
Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition.
Mayo Clin Proc., (2012), 87 pp. 1071-1079
[6]
O. Landgren, B.I. Graubard, J.A. Katzmann, R.A. Kyle, I. Ahmadizadeh, R. Clark, et al.
Racial disparities in the prevalence of monoclonal gammopathies: a population based study of 12,482 persons from the National Health and nutritional examination survey.
Leukemia., (2014), 28 pp. 1537-1542
[7]
O. Landgren, S.V. Rajkumar, R.M. Pfeiffer, R.A. Kyle, J.A. Katzmann, A. Dispenzieri, et al.
Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women.
Blood., (2010), 116 pp. 1056-1059
[8]
A.J. Greenberg, S.V. Rajkumar, C.M. Vachon.
Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.
Blood., (2012), 119 pp. 5359-5366
[9]
O. Landgren, S.Y. Kristinsson, L.R. Goldin, N.E. Caporaso, C. Blimark, U.H. Mellqvist, et al.
Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden.
Blood., (2009), 114 pp. 791-795
[10]
C.M. Vachon, R.A. Kyle, T.M. Therneau, B.J. Foreman, D.R. Larson, C.L. Colby, et al.
Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance.
Blood., (2009), 114 pp. 785-790
[11]
A.J. Greenberg, S.V. Rajkumar, D.R. Larson, D.R. Larson, A. Dispenzieri, T.M. Therneau, et al.
Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma.
Br J Haematol., (2012), 157 pp. 472-475
[12]
S. Anguille, C. Bryant.
Monoclonal gammopathy of undetermined significance.
CMAJ., (2013), 185 pp. 1345
[13]
S. Vanderschueren, M. Mylle, D. Dierickx, M. Delforge, P. Verhamme, K. Peerlinck, et al.
Monoclonal gammopathy of undetermined significance: significant beyond hematology.
Mayo Clin Proc., (2009), 84 pp. 842-845
[14]
D. Rossi, L. De Paoli, S. Franceschetti, D. Capello, C. Vendramin, M. Lunghi, et al.
Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance.
Br J Haematol., (2007), 138 pp. 249-252
[15]
E.K. Lindqvist, L.R. Goldin, O. Landgren, C. Blimark, U.H. Mellqvist, I. Turesson, et al.
Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study.
Blood., (2011), 118 pp. 6284-6291
[16]
J.P. Bida, R.A. Kyle, T.M. Therneau, L.J. Melton 3rd, M.F. Plevak, D.R. Larson, et al.
Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.
Mayo Clin Proc., (2009), 84 pp. 685-693
[17]
M.A. Dimopoulos, J. Hillengass, S. Usmani, E2. Zamagni, S. Lentzsch, F.E. Davies, et al.
Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.
J Clin Oncol., (2015), 33 pp. 657-664
[18]
J. Bird, J. Behrens, J. Westin, I. Turesson, M. Drayson, R. Beetham, et al.
UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).
Br J Haematol., (2009), 147 pp. 22-42
[19]
R.S. Go, S.V. Rajkumar.
How I manage monoclonal gammopathy of undetermined significance.
Blood., (2018), 131 pp. 163-173
[20]
R.A. Kyle, D. Larson, T.M. Therneau, A. Dispenzieri, S. Kumar, J.R. Cerhan, et al.
Long term follow up of monoclonal gammopathy of undetermined significance.
N Eng J Med., (2018), 378 pp. 241-249
[21]
A.M. Rajan, S.V. Rajkumar.
Diagnostic evaluation of monoclonal gammopathy of undetermined significance.
Eur J Haematol., (2013), 91 pp. 561-563
[22]
R.A. Kyle, J.F. San Miguel, M.V. Mateos, S.V. Rajkumar.
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Hematol Oncol Clin N Am., (2014), 28 pp. 775-790
